{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:11:41Z","timestamp":1790701901180,"version":"4.1.0"},"reference-count":24,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,10,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Moxetumomab pasudotox (MP) is an immunotoxin that recently received US Food and Drug Administration (FDA) approval for the treatment of hairy cell leukemia (HCL) that has failed at least 2 prior lines of therapy, including a purine analog. MP is a recombinant immunotoxin that consists of an anti-CD22 immunoglobulin variable domain genetically joined to Pseudomonas exotoxin (PE38). Unlike most antibody-drug conjugates, which use a chemical linker, recombinant DNA techniques are used to produce MP. MP and its predecessor, BL22, were initially developed to treat non-Hodgkin lymphoma, acute lymphoblastic leukemia, and HCL. However, MP was found to be particularly effective in HCL due to the high level of CD22 cell-surface expression. The recent pivotal phase 3 trial of MP in relapsed\/refractory HCL demonstrated a durable complete remission rate of 30%, and 85% of complete responders achieved minimal residual disease negativity, which is associated with improved disease-free survival outcomes in HCL. In addition to an exceptional depth of response, MP appears to be less immunosuppressive than purine analogs. MP is generally well tolerated but has unique toxicities, including capillary leak syndrome and hemolytic uremic syndrome, which are poorly understood. This review will encompass the preclinical and clinical development of MP, with particular attention to its current indication in HCL.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000507","type":"journal-article","created":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T20:45:15Z","timestamp":1570567515000},"page":"2905-2910","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":47,"title":["Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval"],"prefix":"10.1182","volume":"3","author":[{"given":"Adam Yuh","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shira Naomi","family":"Dinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,10,8]]},"reference":[{"issue":"1","key":"2019111520534234700_B1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2009-06-195370","article-title":"How I treat hairy cell leukemia","volume":"115","author":"Grever","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2019111520534234700_B2","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/ajh.24936","article-title":"Hairy cell leukemia 2018: update on diagnosis, risk-stratification, and treatment","volume":"92","author":"Troussard","year":"2017","journal-title":"Am J Hematol"},{"issue":"6","key":"2019111520534234700_B3","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2141.2009.07668.x","article-title":"Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis","volume":"145","author":"Else","year":"2009","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111520534234700_B4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.beha.2015.09.004","article-title":"Long-term follow-up after purine analogue therapy in hairy cell leukaemia","volume":"28","author":"Else","year":"2015","journal-title":"Best Pract Res Clin Haematol"},{"issue":"20","key":"2019111520534234700_B5","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.1002\/cncr.25243","article-title":"Hairy cell leukemia: evaluation of the long-term outcome in 121 patients","volume":"116","author":"Zinzani","year":"2010","journal-title":"Cancer"},{"issue":"21","key":"2019111520534234700_B6","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1182\/blood-2009-03-212449","article-title":"Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior","volume":"114","author":"Forconi","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2019111520534234700_B7","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1182\/blood-2003-02-0630","article-title":"Rituximab in relapsed or refractory hairy cell leukemia","volume":"102","author":"Thomas","year":"2003","journal-title":"Blood"},{"issue":"3","key":"2019111520534234700_B8","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1182\/blood-2003-01-0014","article-title":"Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia","volume":"102","author":"Nieva","year":"2003","journal-title":"Blood"},{"issue":"14","key":"2019111520534234700_B9","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2011-04-351502","article-title":"Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia","volume":"118","author":"Ravandi","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2019111520534234700_B10","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/ni1121","article-title":"CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms","volume":"5","author":"Poe","year":"2004","journal-title":"Nat Immunol"},{"issue":"12","key":"2019111520534234700_B11","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.4049\/jimmunol.136.12.4470","article-title":"HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes","volume":"136","author":"D\u00f6rken","year":"1986","journal-title":"J Immunol"},{"issue":"16","key":"2019111520534234700_B12","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.2003.01.082","article-title":"Phase I\/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin\u2019s lymphoma","volume":"21","author":"Leonard","year":"2003","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111520534234700_B13","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/blood.V82.9.2624.2624","article-title":"A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy","volume":"82","author":"Amlot","year":"1993","journal-title":"Blood"},{"issue":"4","key":"2019111520534234700_B14","first-page":"819","article-title":"Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab\u2019 induce regression of subcutaneous human B-cell lymphoma in mice","volume":"53","author":"Kreitman","year":"1993","journal-title":"Cancer Res"},{"issue":"5","key":"2019111520534234700_B15","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood.V90.5.2020","article-title":"Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors","volume":"90","author":"Mansfield","year":"1997","journal-title":"Blood"},{"issue":"18","key":"2019111520534234700_B16","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.1021\/bi00184a014","article-title":"Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions","volume":"33","author":"Reiter","year":"1994","journal-title":"Biochemistry"},{"issue":"20","key":"2019111520534234700_B17","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-11-0487","article-title":"Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox","volume":"17","author":"Kreitman","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"18","key":"2019111520534234700_B18","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1200\/JCO.2008.20.2630","article-title":"Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia","volume":"27","author":"Kreitman","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111520534234700_B19","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1158\/1078-0432.CCR-08-1456","article-title":"CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies","volume":"15","author":"Alderson","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"15","key":"2019111520534234700_B20","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1200\/JCO.2011.38.1756","article-title":"Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia","volume":"30","author":"Kreitman","year":"2012","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111520534234700_B21","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2017-09-803072","article-title":"Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up","volume":"131","author":"Kreitman","year":"2018","journal-title":"Blood"},{"issue":"suppl 13","key":"2019111520534234700_B22","doi-asserted-by":"crossref","first-page":"Abstract 4595","DOI":"10.1158\/1538-7445.AM2017-4595","article-title":"Moxetumomab pasudotox spares CD4 and CD8 lymphocytes in multiply relapsed hairy cell leukemia patients, while prospective trials of first, second, and later lines of purine analogs show increasing toxicity [abstract]","volume":"77","author":"Kreitman","year":"2017","journal-title":"Cancer Res"},{"issue":"8","key":"2019111520534234700_B23","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1038\/s41375-018-0210-1","article-title":"Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia","volume":"32","author":"Kreitman","year":"2018","journal-title":"Leukemia"},{"issue":"14","key":"2019111520534234700_B24","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1182\/blood-2017-02-749101","article-title":"Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia","volume":"130","author":"Wayne","year":"2017","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/19\/2905\/1223939\/advancesadv2019000507c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/19\/2905\/1223939\/advancesadv2019000507c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T11:46:16Z","timestamp":1695296776000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/19\/2905\/375038\/Moxetumomab-pasudotox-for-hairy-cell-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,8]]},"references-count":24,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2019,10,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000507","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,8]]}}}